Rudolf S N Fehrmann
Overview
Explore the profile of Rudolf S N Fehrmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
4860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knapen D, Hone Lopez S, de Groot D, de Haan J, de Vries E, Dienstmann R, et al.
Commun Med (Lond)
. 2024 May;
4(1):79.
PMID: 38702451
Background: Bulk transcriptional profiles of early colorectal cancer (CRC) can fail to detect biological processes associated with disease-free survival (DFS) if the transcriptional patterns are subtle and/or obscured by other...
2.
Potential imaging targets in primary head and neck squamous cell carcinoma and lymph node metastases
van Schaik J, van der Vegt B, Slagter-Menkema L, Hanemaaijer S, Halmos G, Witjes M, et al.
Am J Otolaryngol
. 2024 Apr;
45(4):104298.
PMID: 38640809
Purpose: To investigate glycoprotein nonmetastatic melanoma protein B (GPNMB) and vascular endothelial growth factor (VEGF) as potential fluorescent imaging markers by comparing their protein expression to epidermal growth factor receptor...
3.
van Schaik J, van der Vegt B, Slagter-Menkema L, van der Laan B, Witjes M, Oosting S, et al.
Oral Oncol
. 2024 Feb;
151:106736.
PMID: 38422829
Objectives: Intraoperative fluorescence imaging (FI) of head and neck squamous cell carcinoma (HNSCC) is performed to identify tumour-positive surgical margins, currently using epidermal growth factor receptor (EGFR) as imaging target....
4.
Bjork J, Bolte L, Thomas A, Lee K, Rossi N, Wind T, et al.
Nat Med
. 2024 Feb;
30(3):785-796.
PMID: 38365950
Multiple clinical trials targeting the gut microbiome are being conducted to optimize treatment outcomes for immune checkpoint blockade (ICB). To improve the success of these interventions, understanding gut microbiome changes...
5.
Metman M, Jonker P, Sondorp L, van Hemel B, Sywak M, Gill A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Nov;
51(8):2384-2394.
PMID: 38017325
Purpose: Multifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the...
6.
van Breugel M, Fehrmann R, Bugel M, Rezwan F, Holloway J, Nawijn M, et al.
Allergy
. 2023 Aug;
78(10):2623-2643.
PMID: 37584170
The field of medicine is witnessing an exponential growth of interest in artificial intelligence (AI), which enables new research questions and the analysis of larger and new types of data....
7.
Stok C, Tsaridou S, van den Tempel N, Everts M, Wierenga E, Bakker F, et al.
Cell Rep
. 2023 Jun;
42(7):112668.
PMID: 37347663
Joint DNA molecules are natural byproducts of DNA replication and repair. Persistent joint molecules give rise to ultrafine DNA bridges (UFBs) in mitosis, compromising sister chromatid separation. The DNA translocase...
8.
van Not O, Wind T, Ismail R, Bhattacharya A, Jalving M, Blank C, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296885
The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients...
9.
Visconti A, Rossi N, Deris H, Lee K, Hanic M, Trbojevic-Akmacic I, et al.
BMC Cancer
. 2023 Feb;
23(1):166.
PMID: 36805683
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients...
10.
Knapen D, de Haan J, Fehrmann R, de Vries E, de Groot D
Crit Rev Oncol Hematol
. 2023 Jan;
183:103918.
PMID: 36702421
There is a clear unmet need to improve early colon cancer management. This review encompasses the current systemic treatment landscape and summarises novel and pivotal trials. The Immunoscore and circulating...